Abstract
The current standard of care for newly diagnosed inoperable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (cCRT) followed by consolidative durvalumab. However, up to 50% of patients are not candidates for cCRT and thus treated with sequential CRT or RT alone, a setting in which immunotherapy is not approved. We launched an investigator-initiated trial to study the safety and outcomes of concurrent and consolidative durvalumab and RT without chemotherapy in patients who are not candidates for cCRT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.